Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Ascletis Files Clinical Trial Applications for Hepatitis C Drugs in China, Taiwan

By Drug Discovery Trends Editor | June 29, 2015

Ascletis today announced that clinical trial applications for its interferon (IFN)-free regimen to treat chronic hepatitis C (CHC) have been filed and accepted by both China Food and Drug Administration (CFDA) and Taiwan Food and Drug Administration (TFDA). Ascletis is now the first Chinese company to file clinical trial applications in China for an IFN-free regimen. This is a significant milestone following the completion of the successful IFN-containing phase II trial in Taiwan region with ASC08, the Company’s leading direct-acting antiviral agent (DAA). This IFN-free regimen contains the NS3/4A inhibitor ASC08 and the NS5A inhibitor ASC16.

“All oral IFN-free regimens are breakthrough treatments of CHC marketed outside China at the end of 2014. To date, there are no DAAs approved in China.” said Professor Zhuang Hui, academician of the Chinese Engineering Academy and the honorary Chairman of the Chinese society of Hepatology, at Peking University Health Science Center, “We’re very pleased that Ascletis is developing the first IFN-free regimen by a domestic company for CHC in China. It shows that the domestic pharmaceutical companies are now catching up with the global development for CHC. This IFN-free regimen is significant for HCV patients in China.”

“Following the recognition of ASC08 triple therapy for CHC at the Asian Pacific Association for the Study of Liver (APASL) annual meeting in March this year, Ascletis is now taking another big step toward development of a highly effective, IFN-free CHC treatment for Chinese patients ,” said Jinzi J. Wu, Ph.D., Ascletis’ founder, President and CEO.

Ascletis is planning several clinical studies to evaluate the combination of ASC08 and ASC16 to treat CHC in mainland China and Taiwan region in the near future.

Source: Ascletis


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50